CompletedPhase 3

Thrombolysis of Urokinase for Minor Stroke

China1,005 participantsStarted 2020-10-04

Plain-language summary

This trial will enroll patients that have been diagnosed with minor stroke, which has occurred within the past 6 hours. TRUST is a prospective multicenter, randomized, blinded-endpoint study to evaluate the efficacy and safety of Urokinase Thrombolysis for patients with minor stroke.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult patients: 18-80 years old
✓. The time from last seen well to treatment \< 6 hours
✓. Minor stroke defined as a baseline NIHSS ≤5 at the time of randomization..
✓. First onset or pre-stroke mRS≤1
✓. Informed consent signed

Exclusion criteria

✕.Hyperdensity on CT suggesting intracranial hemorrhage
✕.Large acute stroke \>1/3 middle cerebral artery (MCA) territory visible on CT or MRI
✕.Other contraindications of intravenous thrombolysis, including but not limited to:
✕. Intracranial tumor, arteriovenous malformation
✕. Coma or confirmed as severe stroke by clinical assessment (e.g. NIHSS ≥25) or proper imaging methods
✕. With seizure
✕. Stroke attack within past three months
✕. Heparin administration within 48h before onset, with APTT longer than upper limit

What they're measuring

Proportion of patients with a modified Rankin Scale(mRS) of 0 or 1 at 90-day follow-up

Timeframe: 90 Days

Proportion of patients with symptomatic intracranial hemorrhage within 36 hours

Timeframe: 36 hours

Trial details

NCT IDNCT04420351

SponsorThe First Affiliated Hospital of Zhengzhou University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-02-18

View on ClinicalTrials.gov More Minor Stroke trials